- Home
- BCDA vs DOMH Comparison
BCDA vs DOMH Comparison
Compare BCDA & DOMH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- DOMH
- Stock Information
- Founded
- BCDA N/A
- DOMH 1967
- Country
- BCDA United States
- DOMH United States
- Employees
- BCDA N/A
- DOMH N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- DOMH Biotechnology: Pharmaceutical Preparations
- Sector
- BCDA Health Care
- DOMH Health Care
- Exchange
- BCDA Nasdaq
- DOMH Nasdaq
- Market Cap
- BCDA 11.3M
- DOMH 94.0M
- IPO Year
- BCDA N/A
- DOMH N/A
- Fundamental
- Price
- BCDA $1.66
- DOMH $6.04
- Analyst Decision
- BCDA Strong Buy
- DOMH
- Analyst Count
- BCDA 1
- DOMH 0
- Target Price
- BCDA $25.00
- DOMH N/A
- AVG Volume (30 Days)
- BCDA 46.4K
- DOMH 304.5K
- Earning Date
- BCDA 11-12-2025
- DOMH 11-07-2025
- Dividend Yield
- BCDA N/A
- DOMH 8.91%
- EPS Growth
- BCDA N/A
- DOMH N/A
- EPS
- BCDA N/A
- DOMH N/A
- Revenue
- BCDA N/A
- DOMH $52,811,000.00
- Revenue This Year
- BCDA N/A
- DOMH N/A
- Revenue Next Year
- BCDA N/A
- DOMH N/A
- P/E Ratio
- BCDA N/A
- DOMH N/A
- Revenue Growth
- BCDA N/A
- DOMH 455.38
- 52 Week Low
- BCDA $1.63
- DOMH $0.83
- 52 Week High
- BCDA $3.25
- DOMH $13.58
- Technical
- Relative Strength Index (RSI)
- BCDA 33.48
- DOMH 50.85
- Support Level
- BCDA $2.11
- DOMH $5.90
- Resistance Level
- BCDA $2.29
- DOMH $7.18
- Average True Range (ATR)
- BCDA 0.11
- DOMH 0.45
- MACD
- BCDA -0.03
- DOMH -0.05
- Stochastic Oscillator
- BCDA 0.15
- DOMH 35.66
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About DOMH Dominari Holdings Inc.
Dominari Holdings Inc through its various subsidiaries, is currently engaged in wealth management, investment banking, securities sales and trading and asset management. The company operates in two reportable business segments: Dominari Financial and Legacy AIkido. The Dominari Financial reportable business segment represents the Company's broker-dealer business, which is composed of mostly underwriting and transactional service activities. The Legacy AIkido reportable business segment includes Aikido Labs, which manages the investments holdings of the legacy entity. It generates the majority of its revenue from the Dominari Financial segment.